Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' (Deficit) Equity

v3.23.3
Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2021 $ 49,376 $ 1 $ 310,011 $ (84) $ (260,552)
Beginning Balance, Shares at Dec. 31, 2021   491,626      
Stock-based compensation 919   919    
Unrealized gain (loss) on marketable securities (140)     (140)  
Net loss (20,157)       (20,157)
Ending balance at Mar. 31, 2022 29,998 $ 1 310,930 (224) (280,709)
Ending balance, Shares at Mar. 31, 2022   491,626      
Beginning Balance at Dec. 31, 2021 49,376 $ 1 310,011 (84) (260,552)
Beginning Balance, Shares at Dec. 31, 2021   491,626      
Net loss (55,313)        
Ending balance at Sep. 30, 2022 (3,103) $ 1 312,901 (140) (315,865)
Ending balance, Shares at Sep. 30, 2022   491,626      
Beginning Balance at Mar. 31, 2022 29,998 $ 1 310,930 (224) (280,709)
Beginning Balance, Shares at Mar. 31, 2022   491,626      
Stock-based compensation 965   965    
Unrealized gain (loss) on marketable securities 11     11  
Net loss (18,089)       (18,089)
Ending balance at Jun. 30, 2022 12,885 $ 1 311,895 (213) (298,798)
Ending balance, Shares at Jun. 30, 2022   491,626      
Stock-based compensation 1,006   1,006    
Unrealized gain (loss) on marketable securities 73     73  
Net loss (17,067)       (17,067)
Ending balance at Sep. 30, 2022 (3,103) $ 1 312,901 (140) (315,865)
Ending balance, Shares at Sep. 30, 2022   491,626      
Beginning Balance at Dec. 31, 2022 (11,852) $ 1 313,884 (32) (325,705)
Beginning Balance, Shares at Dec. 31, 2022   594,983      
Issuance of securities in registered offering 10,000   10,000    
Issuance of securities in registered offering, Shares   128,000      
Financing cost of sale of securities (883)   (883)    
Issuance of common stock for exercise of pre-funded warrants 5   5    
Issuance of common stock for exercise of pre-funded warrants, Shares   842,937      
Stock-based compensation 932   932    
Unrealized gain (loss) on marketable securities 32     32  
Net loss (1,371)       (1,371)
Ending balance at Mar. 31, 2023 (3,137) $ 1 323,938   (327,076)
Ending balance, Shares at Mar. 31, 2023   1,565,920      
Beginning Balance at Dec. 31, 2022 (11,852) $ 1 313,884 $ (32) (325,705)
Beginning Balance, Shares at Dec. 31, 2022   594,983      
Net loss (14,298)        
Ending balance at Sep. 30, 2023 (5,759) $ 1 334,243   (340,003)
Ending balance, Shares at Sep. 30, 2023   10,704,803      
Beginning Balance at Mar. 31, 2023 (3,137) $ 1 323,938   (327,076)
Beginning Balance, Shares at Mar. 31, 2023   1,565,920      
Issuance of common stock for exercise of pre-funded warrants, Shares   2,104,000      
Issuance of common stock for exercise of warrants 7,774   7,774    
Issuance of common stock for exercise of warrants, Shares   7,034,883      
Financing cost of warrant inducement and exercise (414)   (414)    
Reversal of warrant liability due to exercise of warrants 1,442   1,442    
Stock-based compensation 795   795    
Net loss (7,568)       (7,568)
Ending balance at Jun. 30, 2023 (1,108) $ 1 333,535   (334,644)
Ending balance, Shares at Jun. 30, 2023   10,704,803      
Stock-based compensation 708   708    
Net loss (5,359)       (5,359)
Ending balance at Sep. 30, 2023 $ (5,759) $ 1 $ 334,243   $ (340,003)
Ending balance, Shares at Sep. 30, 2023   10,704,803